differential long-term benefit of adjuvant tamoxifen in er /her2- premenopausal postmenopausal bc
Published 1 year ago • 2.2K plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
2:17
25-year benefit from tamoxifen by clinically used breast cancer markers
-
0:38
rxponder: 21-gene assay informs chemotherapy benefit in hr node-positive breast cancer
-
0:59
treatments for hr postmenopausal breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
4:02
assessment of short preoperative endocrine therapy in the adapt and adaptcycle trials
-
3:08
non-adherence to tamoxifen in canto cohort over 3 years
-
8:30
hr breast cancer: endocrine therapy, surgery and radiotherapy
-
1:13
tam-01: low-dose tamoxifen in women with breast intraepithelial neoplasia
-
3:08
the molecular differences between younger versus older er-positive and her2-negative breast cancers
-
3:11
ovarian function suppression in premenopausal women with breast cancer
-
2:59
talent: neoadjuvant t-dxd with or without anastrozole for her2-low, hr early stage breast cancer
-
1:04
data: anastrozole in patients with hr breast cancer following adjuvant tamoxifen
-
4:54
adjuvant hormonal therapy for estrogen receptor positive early stage breast cancer - mayo clinic
-
3:39
comparable outcomes, different toxicities with anastrozole, tamoxifen in dcis | ivana sestak
-
6:13
adjuvant exemestane more effective than tamoxifen (combined with ofs) in women with breast cancer
-
1:56
adjuvant endocrine therapy and risk of contralateral breast cancer
-
3:04
12-year results of anastrozole vs tamoxifen for breast cancer prevention
-
1:32
suzanne a. w. fuqua, phd, discusses the androgen receptor in breast cancer